Country: Romania
Language: English
Source: HMA (Heads of Medicines Agencies)
flunixin meglumine 250 mg
Norbrook Laboratories Limited
QM01AG90
Granules for oral solution
flunixin
Horses
2011-08-23
Revised: August 2011 AN: 00483/2011 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equinixin 25mg/g Granules for Horses (UK) Flunixin 25mg/g Granules for Horses Flunixine Granules 25mg/g for Horses (FR) Flunixin vet 25 mg/g Granules for Horses (FI) Flunimeg 250mg Granules for Horses (DK) Flunixin N-vet 25 mg/g Granules for Horses (SE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 10 g sachet contains: ACTIVE SUBSTANCE Flunixin 250 mg (as flunixin meglumine) EXCIPIENTS For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Granules. White to cream coloured granules 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the alleviation of inflammation and pain associated with musculo-skeletal disorders 4.3 CONTRAINDICATIONS Do not use in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, where there is evidence of a blood dyscrasia or hypersensitivity to the product 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. Revised: August 2011 AN: 00483/2011 Page 2 of 5 4.5 SPECIAL PRECAUTIONS FOR USE i. Special Precautions for use in animals: Do not exceed the recommended dose or the duration of treatment. Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided animals may require a reduced dosage and careful clinical management. Avoid use in any dehydrate Read the complete document